170 related articles for article (PubMed ID: 34583727)
1. Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
Degorre C; Tofilon P; Camphausen K; Mathen P
Radiat Oncol; 2021 Sep; 16(1):191. PubMed ID: 34583727
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.
Mathen P; Rowe L; Mackey M; Smart D; Tofilon P; Camphausen K
Neurooncol Pract; 2020 Jun; 7(3):268-276. PubMed ID: 32537176
[TBL] [Abstract][Full Text] [Related]
3. Deregulated MicroRNA Signature Following Glioblastoma Irradiation.
Toraih EA; El-Wazir A; Abdallah HY; Tantawy MA; Fawzy MS
Cancer Control; 2019; 26(1):1073274819847226. PubMed ID: 31046428
[TBL] [Abstract][Full Text] [Related]
4. Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Ochiai S; Nomoto Y; Yamashita Y; Watanabe Y; Toyomasu Y; Kawamura T; Takada A; Ii N; Kobayashi S; Sakuma H
Asian Pac J Cancer Prev; 2016; 17(2):463-6. PubMed ID: 26925628
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang JE; Khuntia D; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
[TBL] [Abstract][Full Text] [Related]
6. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies.
Li R; Wang H; Liang Q; Chen L; Ren J
Biomater Sci; 2022 Feb; 10(4):892-908. PubMed ID: 34989724
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Radioresponse and Radiosensitizers in Glioblastoma Organotypic Cultures.
Bayin NS; Ma L; Placantonakis DG; Barcellos-Hoff MH
Methods Mol Biol; 2018; 1741():171-182. PubMed ID: 29392699
[TBL] [Abstract][Full Text] [Related]
12. The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.
Pepper NB; Stummer W; Eich HT
Strahlenther Onkol; 2022 Jun; 198(6):507-526. PubMed ID: 35503461
[TBL] [Abstract][Full Text] [Related]
13. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
14. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties.
Lin JC; Tsai JT; Chao TY; Ma HI; Chien CS; Liu WH
Radiother Oncol; 2018 Nov; 129(2):352-363. PubMed ID: 30322656
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
17. GBM radiosensitizers: dead in the water…or just the beginning?
Bindra RS; Chalmers AJ; Evans S; Dewhirst M
J Neurooncol; 2017 Sep; 134(3):513-521. PubMed ID: 28762004
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
19. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
20. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Hosein AN; Lim YC; Day B; Stringer B; Rose S; Head R; Cosgrove L; Sminia P; Fay M; Martin JH
J Neurooncol; 2015 Apr; 122(2):263-71. PubMed ID: 25648357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
